Cogent Biosciences Inc (COGT) — Cash Flow-to-Debt Ratio
Cogent Biosciences Inc (COGT) has a Cash Flow-to-Debt Ratio of -0.26x as of December 2025, meaning its operating cash flow of $-79.11 Million could theoretically repay 0% of its total liabilities ($301.24 Million) in one year. See COGT cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cogent Biosciences Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Cogent Biosciences Inc across 11 annual periods. Also explore net asset growth rate of Cogent Biosciences Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cogent Biosciences Inc (2015–2025)
Year-by-year debt coverage analysis for Cogent Biosciences Inc. For market capitalisation and broader financial context, see Cogent Biosciences Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.88x | $-264.44 Million | $301.24 Million | ▲ +69.7% |
| 2024 | -2.90x | $-207.79 Million | $71.61 Million | ▼ -5.1% |
| 2023 | -2.76x | $-153.62 Million | $55.63 Million | ▼ -4.9% |
| 2022 | -2.63x | $-118.64 Million | $45.08 Million | ▲ +19.8% |
| 2021 | -3.28x | $-58.76 Million | $17.91 Million | ▼ -48.7% |
| 2020 | -2.21x | $-35.85 Million | $16.25 Million | ▲ +6.1% |
| 2019 | -2.35x | $-41.51 Million | $17.66 Million | ▼ -85.9% |
| 2018 | -1.26x | $-32.49 Million | $25.69 Million | ▼ -1.9% |
| 2017 | -1.24x | $-25.84 Million | $20.81 Million | ▼ -54.3% |
| 2016 | -0.80x | $-18.64 Million | $23.16 Million | ▼ -214.7% |
| 2015 | 0.70x | $17.72 Million | $25.25 Million | — |